Cabaletta Bio Inc is a biotechnology company focused on developing innovative cellular therapies for patients with autoimmune diseases. The company specializes in harnessing the power of engineered T cells to target and eliminate disease-causing cells in the body, aiming to provide effective and durable treatments for conditions that currently lack adequate therapeutic options. Through its cutting-edge research and development efforts, Cabaletta Bio seeks to revolutionize the treatment landscape for autoimmune disorders and enhance the quality of life for affected individuals. Read More
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares’ Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing.
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December:
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators –
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off –
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September:
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
